Clinical Trial Update: Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the DTwP-HepB-Hib-IPV (SHAN6) vaccine administered with routine vaccines in healthy infants and toddlers in Thailand has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Haemophilus Influenzae Type Infection
• Hepatitis B
• Pertussis
• Pneumococcal Disease
• Poliomyelitis
• Rotavirus Infection
• Tetanus

Drugs mentioned

• DTwP-HepB-Hib-IPV (SHAN6) vaccine (Diphtheria-Tetanus-whole-cell Pertussis-Hepatitis B-Haemophilus influenzae type B-Inactivated poliovirus vaccine (SHAN6))

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Pertussis Immunisation, Diphtheria Immunisation | Phase 3 | Status: COMPLETED